Therapy Areas: Respiratory
MediLink enters clinical trial collaboration and supply agreement with Amgen
8 October 2024 -

MediLink Therapeutics (Suzhou) Co Ltd, a China-based clinical-stage biotech company, announced on Monday that it has entered into a global clinical trial collaboration and supply agreement with US biopharmaceutical company Amgen Inc (NASDAQ:AMGN).

Under the agreement, Amgen will lead a global clinical study to assess the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE) IMDELLTRA in extensive-stage small cell lung cancer (ES-SCLC). MediLink will provide the investigational drug YL201 for the combination study.

The open-label, multi-centre Phase Ib trial is aimed at assessing the safety, tolerability, pharmacokinetics and efficacy of this combination regimen in ES-SCLC patients.

Both YL201 and IMDELLTRA have shown potential in ES-SCLC.

Login
Username:

Password: